EML4–ALK analysis in CTCs from patients with NSCLC indicated that EML4–ALK+ CTCs are associated with resistance to crizotinib (ALK inhibitor), and thus are a promising candidate for monitoring treatment efficacy and for the early detection of drug resistance [186]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.